Jennifer Croke

ORCID: 0000-0002-7090-6313
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Advances in Oncology and Radiotherapy
  • Endometrial and Cervical Cancer Treatments
  • Advanced Radiotherapy Techniques
  • Economic and Financial Impacts of Cancer
  • Cancer survivorship and care
  • Cervical Cancer and HPV Research
  • Management of metastatic bone disease
  • Prostate Cancer Diagnosis and Treatment
  • Breast Cancer Treatment Studies
  • Ovarian cancer diagnosis and treatment
  • COVID-19 and healthcare impacts
  • Global Cancer Incidence and Screening
  • Radiomics and Machine Learning in Medical Imaging
  • Radiation Dose and Imaging
  • Innovations in Medical Education
  • Palliative Care and End-of-Life Issues
  • MRI in cancer diagnosis
  • Diversity and Career in Medicine
  • Intestinal and Peritoneal Adhesions
  • Radiology practices and education
  • Mentoring and Academic Development
  • Prostate Cancer Treatment and Research
  • Cancer Treatment and Pharmacology
  • Healthcare professionals’ stress and burnout
  • Cancer Genomics and Diagnostics

Princess Margaret Cancer Centre
2014-2024

University Health Network
2016-2024

University of Toronto
2014-2024

Health Net
2018-2023

University of Utah
2022

Huntsman Cancer Institute
2022

CancerCare Manitoba
2021

Dalhousie University
2021

Ottawa Hospital
2011-2020

Radiation Oncology Associates
2019

Most cervical cancers are caused by human papilloma virus (HPV), and HPV circulating tumor DNA (ctDNA) may identify patients at highest risk of relapse. Our pilot study using digital polymerase chain reaction (dPCR) showed that detectable ctDNA the end chemoradiation (CRT) is associated with inferior progression-free survival (PFS) a next-generation sequencing approach (HPV-seq) outperform dPCR. We aimed to prospectively validate as tool for early detection residual disease.

10.1200/jco.23.00954 article EN cc-by Journal of Clinical Oncology 2023-11-16

Purpose: Multidisciplinary cancer conferences (mccs) are designed to optimize patient outcomes. It appears intuitive that mccs essential clinical decision-making and management; however, it is unclear whether belief supported by evidence. Our objectives were assess the currently published literature addressing impact of on Methods: Ovid medline was searched from 1950 June 2010 using these keywords: “multidisciplinary/interdisciplinary/clinical meeting$/conference$/round$/team$,” “decision...

10.3747/co.19.944 article EN cc-by Current Oncology 2012-08-01

10.1016/s1470-2045(20)30085-1 article EN The Lancet Oncology 2020-03-20

Importance Multimodal artificial intelligence (AI) chatbots can process complex medical image and text-based information that may improve their accuracy as a clinical diagnostic management tool compared with unimodal, text-only AI chatbots. However, the difference in of multimodal addressing questions about oncology cases remains to be tested. Objective To evaluate utility prompt engineering (zero-shot chain-of-thought) compare competency unimodal generate medically accurate responses cases....

10.1001/jamanetworkopen.2024.37711 article EN cc-by-nc-nd JAMA Network Open 2024-10-23

To determine whether plasma human papillomavirus (HPV) DNA predates clinical recurrence and compare its accuracy with 3-month fluorodeoxyglucose positron emission tomography (FDG-PET) in locally advanced cervical cancer.This prospective multicenter study accrued 23 women stage IB to IVA cancer planned for definitive chemoradiation therapy (CRT). Plasma HPV was measured serially by digital polymerase chain reaction, FDG-PET performed at 3 months post-CRT.Of the 19 HPV+ included this analysis,...

10.1200/po.18.00152 article EN JCO Precision Oncology 2018-09-13

Tumor hypoxia is associated with poor response to radiation (RT). We previously discovered a novel mechanism of metformin: enhancing tumor RT by decreasing hypoxia. hypothesized that metformin would decrease and improve cervical cancer RT.A window-of-opportunity, phase II randomized trial was performed in stage IB-IVA cancer. Patients underwent screening positron emission tomography (PET) imaging tracer fluoroazomycin arabinoside (FAZA). Only patients FAZA uptake (hypoxic tumor) were...

10.1158/1078-0432.ccr-22-1665 article EN Clinical Cancer Research 2022-08-29

Malignant bowel obstruction (MBO) is a common and distressing complication in women with advanced gynecologic cancer. A pilot, interprofessional MBO program was launched 2016 at large Canadian tertiary cancer center to integrate these patients' complex care needs across multiple disciplines support MBO.Retrospective analysis evaluate the outcomes of who were admitted hospital because MBO, before (2014 2016: baseline group) after (2016 2018) implementation program.Of 169 evaluated, 106 63...

10.1200/jop.18.00793 article EN cc-by-nc-nd Journal of Oncology Practice 2019-09-24

Findings from clinical trials have led to advancement of care for patients with gynecologic malignancies. However, restrictive inclusion into has been widely criticized inadequate representation the real-world population. Ideally, enrolled in should represent a broader population enhance external validity and facilitate translation outcomes across all relevant groups. Specifically, there systematic lack data underrepresented groups, many studies failing report or differentiate study...

10.1136/ijgc-2024-005982 article EN cc-by-nc International Journal of Gynecological Cancer 2024-11-01

Mitigation strategies to balance the risk of coronavirus disease 2019 (COVID-19) infection against oncologic in patients with breast cancer undergoing radiation therapy have been deployed. To this end, shorter hypofractionated regimens recommended where appropriate, prioritization by and omission or deferral for lower cases. Timely adoption these measures reduces COVID-19 both health care workers preserves resources. Herein, we present our early response adaptation utilization during...

10.1016/j.adro.2020.06.002 article EN cc-by-nc-nd Advances in Radiation Oncology 2020-06-19

Background: Improved treatments resulting in a rising number of survivors breast cancer (bca) calls for optimization current specialist-based follow-up care. In the present study, we evaluated well bca with respect to their supportive care needs and attitudes toward various providers, varying settings, or mediated by technology (for example, videoconference e-mail). Methods: A cross-sectional paper survey early-stage pT1–2N0 undergoing posttreatment was completed. Descriptive univariable...

10.3747/co.26.4131 article EN cc-by Current Oncology 2019-04-01

Recurrence rates following radiotherapy for prostate cancer in the post-operative adjuvant or salvage setting remain substantial. Previous work from our institution demonstrated that published bed CTV guidelines frequently do not cover pre-operative MRI defined prostate. Inadequate target delineation may contribute to high recurrence rates, but increasing volumes increase dose organs at risk. We propose delineating post-prostatectomy based upon an individual's co-registered MRI. MRI-based...

10.1186/s13014-014-0303-6 article EN cc-by Radiation Oncology 2014-12-01

Mentorship is a key factor in promoting and maintaining fulfillment medical practice. Invariably, physician success stories usually have common thread: an important mentor, or mentors, whose guidance proved invaluable. Finding mentors has been noted as challenge for women radiation oncology given low representation the field.1Barry PN Miller KH Ziegler C Hertz R Hanna N Dragun AE. Factors affecting gender-based experiences residents oncology.Int J Radiat Oncol Biol Phys. 2016; 95:...

10.1016/j.adro.2021.100686 article EN cc-by-nc-nd Advances in Radiation Oncology 2021-03-15

Objective Wee1 kinase is a crucial regulator of the G2/M checkpoint which prevents entry damaged DNA into mitosis. Adavosertib (AZD1775), selective inhibitor Wee1, induces G2 escape and increases cytotoxicity when combined with damaging agents. We aimed to evaluate safety efficacy adavosertib in combination definitive pelvic radiotherapy concurrent cisplatin patients gynecological cancers. Methods A multi-institutional, open-label phase I trial was designed assess dose escalation (3+3...

10.1136/ijgc-2023-004491 article EN cc-by-nc-nd International Journal of Gynecological Cancer 2023-06-28
Coming Soon ...